-
Another fluoroquinolone has been added to the list of antibacterial agents for respiratory tract infections. Gemifloxacin is a broad-spectrum agent that is highly active against the most common respiratory pathogens, including penicillin and macrolide resistant Streptococcus pneumoniae.
-
Impaired Fasting Glucose vs Impaired Glucose Tolerance; Risk Stratification in Long-QT Syndrome; EBCT, Motivation, Behavioral Change, and Cardiovascular Risk Profile
-
A Strategy to Reduce Cardiovascular Disease by More Than 80 Percent; Pearly Penile Papules: Still No Reason for Uneasiness; The Epidemiology of Major Depressive Disorder
-
Only about 12% of patients with new onset atrial fibrillation who did not have apparent contraindications to warfarin treatment filled prescriptions for it.
-
Peripheral arterial disease is common. Screening with measurement of the ankle-brachial index will improve detection.
-
The low-carbohydrate diet produced a greater weight loss than did the conventional diet for the first 6 months, but the differences were not significant at 1 year.
-
The association of caffeine and nicotine in pharmaceutical products and aneurysmal SAH warrants further study.
-
Women who survive breast cancer may be at a lower risk of developing coronary artery disease compared with women without a history of breast cancer.
-
The FDA has approved the first once-daily protease inhibitor (PI) for the treatment of HIV-1 infections. Atazanavir (Bristol-Myers Squibb) is the newest PI to enter this relatively crowded class. It is marketed under the trade name Reyataz.
-
Elevated homocysteine levels have been associated with atherosclerosis. Folic acid supplementation is a simple, inexpensive way to reduce homocysteine levels, which has become popular for secondary prevention in patients with coronary artery disease (CAD), despite a paucity of long-term clinical trial data. Thus, Liem and colleagues studied 593 patients with stable CAD on statins who were randomized to open-label folic acid 0.5 mg/d or standard care, which included aggressive pursuit of lipid goals.
